CMIC HOLDINGS Co., Ltd. (the “Company”) hereby announces the following revisions to the forecasts of the full-year consolidated results announced on January 31, 2022 for the fiscal year ending September 2022.

Notes

１．Revision of FY2022 Full-year Forecast (October 1, 2021 to September 30, 2022)

Sales Operating income Ordinary income Profit attributable to owners of parent Earnings per share
Previous forecast (A)（A)
（2022/1/31）
 Millions of yen
95,000		 Millions of yen
6,000		 Millions of yen
5,800		 Millions of yen
3,000		 yen
165.82
Current revised forecast（B） 97,000 7,600 7,800 3,900 217.30
Increase
（B-A）
 2,000 1,600 2,000 900 ‐
Rate of change
（％）
 2.1 26.7 34.5 30.0 ‐
(Reference) Results for the previous fiscal year
(FY2021)
 85,788 4,920 5,091 2,023 111.85

(Reasons for amendment)
The outlook for the fiscal year ending September 30, 2022, incorporates the outlook for future work related to COVID-19 and the impact of the situation in Ukraine on our business, based on information available at this time.

With regard to operations related to new coronavirus infection, while therapeutic drug and vaccine development projects are expected to continue, large-scale vaccination projects, which had driven our performance in the first half of the current fiscal year, are expected to decline.
As for the impact of the situation in Ukraine, although the Group does not have any business sites in Russia or Ukraine, there is a possibility that clinical trials in both countries will be cancelled or postponed, or that procurement of raw materials, medical equipment, and other materials will be delayed due to logistical disruptions, which may cause changes in our plans for contract projects. In addition, higher energy and logistics costs are expected to have an impact on profits.

Based on the above, we have revised upward our full-year forecasts for the fiscal year ending September 30, 2022, to net sales of 97,000 million yen, operating income of 7,600 million yen, ordinary income of 7,800 million yen, and net income attributable to owners of the parent of the company of 3,900 million yen, respectively, in light of continued strong performance in vaccine development and vaccination support services for new coronavirus infection during the first half of the current fiscal year.

PDF Click Here to Read Now